The role of fibroblast growth factor 9 (FGF9)
Researchers at the Institute for Respiratory Health employ various in vitro techniques and preclinical models to investigate novel therapies for malignant pleural disease and mesothelioma.
FGF-9 is an exciting and novel target uncovered from global gene profiling of human malignant pleural mesothelioma (MPM) samples.
Researcher have verified over-expression of FGF-9 in MPM over other cancers and benign pleuritis in five separate cohorts of human pleural tissues and effusions. Preliminary in vitro work shows that FGF-9 induces mesothelioma cell proliferation and matrix invasion, and knock-down of FGF-9 retards MPM growth in mice.
This data is the first to suggest a central role of FGF-9 in the biology of MPM and current studies are aimed at assessing anti-FGF-9 strategies for clinical translation. In addition, findings show that FGF-9 inhibits the antitumour immune response in mesothelioma. We are currently determining the mechanism for this novel role for FGF-9.
To get involved or for more information, contact the Research Leader.
Dr Sally Lansley
Senior Research Fellow